BlackRock
TEVA icon

BlackRock’s Teva Pharmaceuticals TEVA Stock Holding History

BlackRock’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-5,000
Closed -$77K – 5045
2018
Q4 		$77K Buy
+5,000
New +$103K ﹤0.01% 4402
2014
Q2 		– Sell
-175,000
Closed -$9.25M – 3222
2014
Q1 		$9.25M Buy
+175,000
New +$8.09M 0.01% 691

Other funds holding TEVA

HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock's TEVA Position: Q2 2026 in Review

BlackRock reduced its Teva Pharmaceuticals (TEVA) stake by 1.9% in Q2 2026, selling an estimated $41.4M and leaving 63,894,301 shares worth $2.16B. The position accounts for 0.03% of the portfolio, ranked #423.

BlackRock first reported a position in TEVA in Q1 2014 and has held it in 50 quarters since. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • BlackRock held 63,894,301 shares of Teva Pharmaceuticals worth $2.16B as of Q2 2026.
  • BlackRock sold 1,242,163 Teva Pharmaceuticals shares in Q2 2026, an estimated $41.4M.
  • Teva Pharmaceuticals made up 0.03% of BlackRock's portfolio in Q2 2026, its #423 holding.
  • BlackRock first reported a position in Teva Pharmaceuticals in Q1 2014 and has held it in 50 quarters since.
  • 676 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.